NASDAQ:SUPN - Supernus Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $36.07 +1.01 (+2.88 %) (As of 04/19/2019 04:00 PM ET)Previous Close$35.06Today's Range$33.4585 - $36.2152-Week Range$30.05 - $61.25Volume960,596 shsAverage Volume571,377 shsMarket Capitalization$1.89 billionP/E Ratio17.60Dividend YieldN/ABeta1.59 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Supernus Pharmaceuticals, Inc., a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine. The company's product candidates comprise SPN-812, a viloxazine hydrochloride, which is in Phase III clinical trial that is used for the treatment of attention deficit hyperactivity disorder (ADHD); SPN-810, a molindone hydrochloride that is in Phase III clinical trial for the treatment of impulsive aggression in patients with ADHD; SPN-809, a viloxazine hydrochloride, which is in Phase II ready clinical trial for the treatment of depression; SPN-604 extended release oxcarbazepine for bipolar; and SPN-817 that is in phase I clinical trial for treating epilepsy. The company markets its products through wholesalers and distributors. Supernus Pharmaceuticals, Inc. was founded in 2005 and is based in Rockville, Maryland. Receive SUPN News and Ratings via Email Sign-up to receive the latest news and ratings for SUPN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:SUPN Previous Symbol CUSIP86845910 CIK1356576 Webwww.supernus.com Phone301-838-2500Debt Debt-to-Equity Ratio0.73 Current Ratio3.06 Quick Ratio2.90Price-To-Earnings Trailing P/E Ratio17.60 Forward P/E Ratio15.22 P/E GrowthN/A Sales & Book Value Annual Sales$408.90 million Price / Sales4.62 Cash Flow$2.3468 per share Price / Cash Flow15.37 Book Value$8.67 per share Price / Book4.16Profitability EPS (Most Recent Fiscal Year)$2.05 Net Income$110.99 million Net Margins27.14% Return on Equity27.45% Return on Assets12.41%Miscellaneous Employees448 Outstanding Shares52,320,000Market Cap$1.89 billion Next Earnings Date5/14/2019 (Estimated) OptionableOptionable Supernus Pharmaceuticals (NASDAQ:SUPN) Frequently Asked Questions What is Supernus Pharmaceuticals' stock symbol? Supernus Pharmaceuticals trades on the NASDAQ under the ticker symbol "SUPN." How were Supernus Pharmaceuticals' earnings last quarter? Supernus Pharmaceuticals Inc (NASDAQ:SUPN) released its quarterly earnings results on Tuesday, February, 26th. The specialty pharmaceutical company reported $0.48 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.27 by $0.21. The specialty pharmaceutical company had revenue of $113.50 million for the quarter, compared to the consensus estimate of $105.36 million. Supernus Pharmaceuticals had a net margin of 27.14% and a return on equity of 27.45%. The company's quarterly revenue was up 31.4% on a year-over-year basis. During the same period last year, the firm earned $0.26 earnings per share. View Supernus Pharmaceuticals' Earnings History. When is Supernus Pharmaceuticals' next earnings date? Supernus Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, May 14th 2019. View Earnings Estimates for Supernus Pharmaceuticals. What guidance has Supernus Pharmaceuticals issued on next quarter's earnings? Supernus Pharmaceuticals updated its FY 2019 earnings guidance on Tuesday, February, 26th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $435-455 million, compared to the consensus revenue estimate of $456.02 million. What price target have analysts set for SUPN? 7 brokerages have issued 12-month target prices for Supernus Pharmaceuticals' stock. Their predictions range from $44.00 to $65.00. On average, they expect Supernus Pharmaceuticals' stock price to reach $57.4286 in the next year. This suggests a possible upside of 59.2% from the stock's current price. View Analyst Price Targets for Supernus Pharmaceuticals. What is the consensus analysts' recommendation for Supernus Pharmaceuticals? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Supernus Pharmaceuticals in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Supernus Pharmaceuticals. What are Wall Street analysts saying about Supernus Pharmaceuticals stock? Here are some recent quotes from research analysts about Supernus Pharmaceuticals stock: 1. Mizuho analysts commented, "We believe the Day failed to rally SUPN because of the cautious body language around the SPN-810 asset in impulsive aggression. We believe investors may avoid the pending Phase III SPN-810 impulsive aggression read-out in 2H:19 (next big catalyst/clearing event for the stock) because mgmt. highlighted the pioneering aspects of its program, and its unprecedented reliance on daily caregiver data reports. We reiterate our Buy rating as SUPN trades below our $47 bear case valuation which assigns no value to SPN-810." (4/17/2019) 2. According to Zacks Investment Research, "Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland. " (3/14/2019) 3. Cantor Fitzgerald analysts commented, "We anticipate the core Trokendi XR and Oxtellar XR businesses will continue to perform well, particularly the former, with the ongoing roll-out for the migraine prevention indication. Over the next 12-24 months, with provision of positive clinical trial data, we believe investors will better appreciate the value of pipeline assets the bipolar indication opportunity for Oxtellar XR. $57 price target is based on DCF and SOP analyses that forecast peak Oxtellar XR and Trokendi XR sales of $170 million (by 2026) and $450 million (2021) respectively." (2/27/2019) Has Supernus Pharmaceuticals been receiving favorable news coverage? Media coverage about SUPN stock has trended somewhat positive recently, according to InfoTrie. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Supernus Pharmaceuticals earned a news sentiment score of 1.0 on InfoTrie's scale. They also gave news articles about the specialty pharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the next few days. Who are some of Supernus Pharmaceuticals' key competitors? Some companies that are related to Supernus Pharmaceuticals include Marina Biotech (MRNA), Jazz Pharmaceuticals (JAZZ), Loxo Oncology (LOXO), Beigene (BGNE), Dr.Reddy's Laboratories (RDY), Perrigo (PRGO), Catalent (CTLT), GALAPAGOS NV/S (GLPG), Amarin (AMRN), Nektar Therapeutics (NKTR), Alkermes (ALKS), Array Biopharma (ARRY), GW Pharmaceuticals PLC- (GWPH), Horizon Pharma (HZNP) and Ascendis Pharma A/S (ASND). What other stocks do shareholders of Supernus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Supernus Pharmaceuticals investors own include NVIDIA (NVDA), Alibaba Group (BABA), Exelixis (EXEL), AbbVie (ABBV), Gilead Sciences (GILD), GW Pharmaceuticals PLC- (GWPH), Baozun (BZUN), Netflix (NFLX), Celgene (CELG) and Synergy Pharmaceuticals (SGYP). Who are Supernus Pharmaceuticals' key executives? Supernus Pharmaceuticals' management team includes the folowing people: Mr. Jack A. Khattar, Founder, Pres, CEO, Sec. & Director (Age 58)Mr. Gregory S. Patrick, VP & CFO (Age 68)Dr. Padmanabh P. Bhatt, Chief Scientific Officer & Sr. VP of Intellectual Property (Age 62)Dr. Stefan K. F. Schwabe, Chief Medical Officer and Exec. VP of R&D (Age 67)Dr. Todd Horich M.B.A., Ph.D., VP of Marketing Who are Supernus Pharmaceuticals' major shareholders? Supernus Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Scout Investments Inc. (1.47%), Ingalls & Snyder LLC (0.33%), Strs Ohio (0.17%), Baltimore Washington Financial Advisors Inc. (0.09%), Campbell Newman Asset Management Inc. (0.03%) and Juncture Wealth Strategies LLC (0.02%). Company insiders that own Supernus Pharmaceuticals stock include Gregory S Patrick, Padmanabh P Bhatt, Stefan KF Schwabe and Victor Vaughn. View Institutional Ownership Trends for Supernus Pharmaceuticals. Which major investors are selling Supernus Pharmaceuticals stock? SUPN stock was sold by a variety of institutional investors in the last quarter, including Scout Investments Inc., Juncture Wealth Strategies LLC and Ingalls & Snyder LLC. Company insiders that have sold Supernus Pharmaceuticals company stock in the last year include Gregory S Patrick, Padmanabh P Bhatt, Stefan KF Schwabe and Victor Vaughn. View Insider Buying and Selling for Supernus Pharmaceuticals. Which major investors are buying Supernus Pharmaceuticals stock? SUPN stock was bought by a variety of institutional investors in the last quarter, including Strs Ohio, Eqis Capital Management Inc., Sciencast Management LP, Nisa Investment Advisors LLC, Baltimore Washington Financial Advisors Inc., Huntington National Bank and Campbell Newman Asset Management Inc.. View Insider Buying and Selling for Supernus Pharmaceuticals. How do I buy shares of Supernus Pharmaceuticals? Shares of SUPN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Supernus Pharmaceuticals' stock price today? One share of SUPN stock can currently be purchased for approximately $36.07. How big of a company is Supernus Pharmaceuticals? Supernus Pharmaceuticals has a market capitalization of $1.89 billion and generates $408.90 million in revenue each year. The specialty pharmaceutical company earns $110.99 million in net income (profit) each year or $2.05 on an earnings per share basis. Supernus Pharmaceuticals employs 448 workers across the globe. What is Supernus Pharmaceuticals' official website? The official website for Supernus Pharmaceuticals is http://www.supernus.com. How can I contact Supernus Pharmaceuticals? Supernus Pharmaceuticals' mailing address is 1550 E GUDE DR, ROCKVILLE MD, 20850. The specialty pharmaceutical company can be reached via phone at 301-838-2500 or via email at [email protected] MarketBeat Community Rating for Supernus Pharmaceuticals (NASDAQ SUPN)Community Ranking: 3.2 out of 5 ( )Outperform Votes: 401 (Vote Outperform)Underperform Votes: 224 (Vote Underperform)Total Votes: 625MarketBeat's community ratings are surveys of what our community members think about Supernus Pharmaceuticals and other stocks. Vote "Outperform" if you believe SUPN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SUPN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 4/19/2019 by MarketBeat.com StaffFeatured Article: What are the benefits of investing in REITs?